RxDoctor Payments Data

Mark Albert, MD

Plastic and Reconstructive Surgery · New York, NYNPI 1598086910

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.1%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Johnson & Johnson at 33.0% of the total. Reporting peaked in 2019 at $3,708 and has fallen 99.6% since, to $16 in 2025.

$5,081in general payments, 2019–2025

Across 27 payments — averaging $188.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$1K
  • KCI USA, Inc.$1K
  • Sientra, Inc.$497
  • Musculoskeletal Transplant Foundation Inc.$196
  • Mentor Worldwide LLC$166
  • plus $278 from 4 others
$150,000in research payments, 2019–2025

Across 5 payments — averaging $30,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • KCI USA, Inc.$75K
  • Solventum Corporation$75K

What the payments were for

  • Consulting fees$2,29045%
  • Travel & lodging$501%
  • Food & beverage$1,71434%
  • Gifts$1,02720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,081 in reported general payments places this provider in the 75th percentile of 219 plastic and reconstructive surgery providers in New York.

See all plastic and reconstructive surgery providers in New York

Medicare billing

Part B allowed, 2024
$200,265
Medicare patients
119
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin13$54

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →